About
In this webinar, Dr. Brady Wu discusses bispecific antibody drugs and their production.

First, he provides a comprehensive overview of the history and development of bispecific antibodies (BsAbs), including their structural biology and strategies like the "common light chain (cLC) approach" to resolve chain mispairing issues. Next, he elaborates on the mechanisms of action of BsAb drugs and challenges in selecting the most active bispecific candidates: currently, over 100 BsAb structural formats exist, with most designed using "knobs-into-holes (KIH)" engineering principles.

Regarding BsAb production, Dr. Wu highlights Biointron's expertise in molecular formats like KIH, IgG-scFv, and IgG-VHH, and presents solutions for addressing molecular mispairing and impurity removal during manufacturing. Additionally, he shares case studies and strategies to enhance antibody expression levels and optimize purification processes to meet diverse client requirements.

Finally, Dr. Wu introduces his company's infrastructure, R&D advantages in bispecific/multispecific antibody fields, and service features. This includes discussions on platform technologies for accelerating therapeutic development and customized solutions for complex antibody engineering challenges.

Key Topics:

  • Explore the journey of bispecific antibodies from their 1980s origins to cutting-edge products and platforms

  • Discuss breakthroughs in the therapeutic area including oncology/immunotherapy

  • Analyze the key hurdles in production: structural complexity, stability, and scalable production

Presenter
1744725030-7cd668d5f0c7a387
Brady Wu, PhD
Head of Protein Center
Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China's top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Country / Region*
Job Title*
Organization / Company*
Organization Type*
Have you heard of Biointron?*
Yes
No
What is your primary interest in bispecific antibodies?*
utm_bmcr_source
Registration Terms
This event is hosted by Scientist.com. By registering and participating, you acknowledge that your personal data will be processed by Scientist.com. You also agree to receive email communication from Scientist.com about this webinar and other programs of similar nature. The sponsor of this webinar is Biointron; by registering and participating, you acknowledge that your data will be processed in accordance with Biointron's Privacy Policy. You will receive email communication from Biointron about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Scientist.com Privacy Policy
✓ Yes, I consent to the registration terms.*
Biointron Privacy Policy
✓ Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.
Powered by BigMarker